Experimental study investigates ivermectin's impact on inflammatory markers in rats with induced vasculitis, suggesting therapeutic potential.
Introduction: Vasculitis is the inflammation of the blood vessel walls and tissues, affecting single organs or multiple systems and is often a hidden factor in numerous disorders. Different pathogens induce innate and adaptive immune system cells to release pro-inflammatory cytokines. These processes lead to the production of proteolytic enzymes, oxidative stress, vascular homeostasis disruption, and destruction of endothelial cells. Objectives: This study aims to investigate the immunomodulatory effects of ivermectin on the rat vasculitis model. Materials and Methods: This experimental animal study included 33 male Wistar albino rats which were divided into five groups. The disease was induced in all groups except group I (control); rats of this group received the dissolving vehicles only. Group II (vasculitis induction group) received ovalbumin and lipopolysaccharide (LPS). Group III, group IV and group V (ivermectin groups) were pretreated with 0.5 mg/kg, 1 mg/kg and 1.5 mg/kg of ivermectin, respectively, for seven days, followed by vasculitis induction using ovalbumin and LPS. Results: This study showed a significant reduction (P<0.001) in serum interleukin-6 (IL-6), C-reactive protein (CRP) and myeloperoxidase (MPO) anti-neutrophil cytoplasmic antibody (ANCA) levels in rats who received ivermectin compared to the disease group. Immunohistochemistry staining of Toll-like receptor 4 (TLR4) showed a decrease in the expression of this receptor in ivermectin groups. Conclusion: Ivermectin modulates inflammatory reactions by inhibiting inflammatory marker expression. Therefore, ivermectin can be effective in protecting against the disease.
No takes yet. Share an insight, caveat, or question.
Sadeq et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: